As the year winds down, diagnostic deals aren't as plentiful. Nevertheless, there have been some significant transactions. Here's a recap of the key activity from mid-October through the third week of … [Read more...]

The swirl of autumn leaves has brought a swirl of diagnostic deals. Here's a recap of the key activity from mid-September through the third week of October. M&A and Asset Sales Quest Diagnostics … [Read more...]

Amid back to school season, companies were back to making diagnostic deals. Here's a recap of the key activity from mid-August through the third week of September.  M&A and Asset Sales This … [Read more...]

Forget the lazy days of summer–lab companies have been moving forward with deals. Here's a look at key activity from mid-July through the third week of August. M&A Roche acquired an additional … [Read more...]

After last month’s flurry of transactions, business calmed down as it often does during the start of summer. Here are the key deals and trends from mid-June through the third week of … [Read more...]

Mid-May to mid-June was the busiest period of the year for diagnostic deal making in terms of both volume and magnitude. Here is a look at the highlights. M&A Dollar value-wise, the biggest lab … [Read more...]

The pace of deal making has picked up a bit, but deal volume remains relatively low on both the M&A and strategic alliance fronts. As usual, smaller molecular and genomics firms are supplying … [Read more...]

While M&A activity in the wider healthcare industry is heating up deal making in the diagnostics space remains relatively light, not so much in terms of volume but in size, at least compared to … [Read more...]

Based on the early returns, the market analysts that predicted 2018 would see a slowdown in strategic Dx deal making appear to be right. But while deal volume was low on both the M&A and alliance … [Read more...]